Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (1-10 of 236) with videos related to

Pageof 24
Sort By:
Seminars in Oncology|March 23, 2011
Molecular profiling of melanoma and the evolution of patient-specific therapyThomas F Gajewski
The New England Journal of Medicine|February 19, 2005
Lymphoma-infiltrating immune cellsThomas F Gajewski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironmentThomas F Gajewski
Molecular Oncology|January 18, 2012
Cancer immunotherapyThomas F Gajewski
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Integrating IL-12 into therapeutic cancer vaccinesThomas F Gajewski
Immunity|August 29, 2007
The expanding universe of regulatory T cell subsets in cancerThomas F Gajewski
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Update on vaccines for solid tumorsThomas F Gajewski
Clinical Advances in Hematology & Oncology : H&O|July 7, 2020
Strategies to overcome resistance to PD-1 inhibitorsThomas F Gajewski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2004
Temozolomide for melanoma: new toxicities and new opportunitiesThomas F Gajewski
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1Thomas F Gajewski
Pageof 24

Showing results (1-10 of 236) with videos related to

Sort By:
Pageof 24
Seminars in Oncology|March 23, 2011
Molecular profiling of melanoma and the evolution of patient-specific therapyThomas F Gajewski
The New England Journal of Medicine|February 19, 2005
Lymphoma-infiltrating immune cellsThomas F Gajewski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironmentThomas F Gajewski
Molecular Oncology|January 18, 2012
Cancer immunotherapyThomas F Gajewski
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Integrating IL-12 into therapeutic cancer vaccinesThomas F Gajewski
Immunity|August 29, 2007
The expanding universe of regulatory T cell subsets in cancerThomas F Gajewski
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Update on vaccines for solid tumorsThomas F Gajewski
Clinical Advances in Hematology & Oncology : H&O|July 7, 2020
Strategies to overcome resistance to PD-1 inhibitorsThomas F Gajewski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2004
Temozolomide for melanoma: new toxicities and new opportunitiesThomas F Gajewski
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1Thomas F Gajewski
Pageof 24